Cosibelimab

DRUG4 trials

Sponsors

TG Therapeutics, Inc., Checkpoint Therapeutics, Inc., Arsen Osipov, Dana-Farber Cancer Institute

Conditions

B-cell Non Hodgkin LymphomaCutaneous Squamous Cell CarcinomaMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Pancreatic Ductal AdenocarcinomaRichter's TransformationSkin Cancer

Phase 1

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

TerminatedNCT03778073

TG Therapeutics, Inc.B-cell Non Hodgkin Lymphoma, Richter's Transformation

Start: 2019-04-17End: 2022-08-01Updated: 2022-08-22

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruitingNCT06981806

Arsen OsipovMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2026-01-31End: 2027-02-28Target: 24Updated: 2025-11-19

Phase 3

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

TerminatedNCT04786964

Checkpoint Therapeutics, Inc.Metastatic Non-squamous Non Small Cell Lung Cancer

Start: 2021-12-08End: 2023-12-30Updated: 2025-04-02

Phase 4

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Not yet recruitingNCT07426484

Dana-Farber Cancer InstituteCutaneous Squamous Cell Carcinoma, Skin Cancer

Start: 2026-07-01End: 2032-12-15Target: 80Updated: 2026-02-23